A par value of the pharmaceutical company is equal to 1 thous. UAH, and the total quantity is 1 mln ps. The bonds will be produced in lots, with 100 thous. ps in each. However the company does not stipulate for bonds for stocks exchange.
Ukrsibbank will become the underwriter of «Darnitsa» bond flotation; these bonds will be floated for a term of 10 years with an annual revenue rate of 30%.
It is currently reported that a total par value of bond flotation is equal to the cost of stockholder equity, which is 1, 193 billion UAH.
It is known that the half of the facilities, which were obtained after the sale, will go to buying the rights of intellectual property and usage policy for industry engineering of a new medical product in Ukraine. The other half will be used for buying materials for pharmaceutical production, including active pharmaceutical ingredients.
During 2014 the clean profit of «Darnitsa» increased 47,8% to 295, 955 mln UAH, and a clean profit increased 2,5% to 1,2 billion UAH.
Currently Kyiv pharmaceutical company is one of the 10 biggest Ukrainian pharmaceutical manufacturers and is a top 10 hospital supplier.
The current productive capacity of the company produces more than 400 mln ampoules, 4 bln pills, 30 mln flacks of antibiotics, more than 30 mln tubes of soft dosage forms, 35 mln flasks of drops and more than 16 mln flasks of infusion solution.
